Immunotherapy, a groundbreaking approach in the field of oncology, has revolutionized the treatment of various malignancies. This guide aims to provide an in-depth understanding of the principles and applications of immunotherapy.
Immunotherapy refers to treatments that use the body's immune system to fight diseases, particularly cancer. It can be classified into two main types: active and passive. Active immunotherapy stimulates the patient's immune system to attack the tumor cells, while passive immunotherapy involves the administration of immune system components, such as monoclonal antibodies.
Immunotherapy has shown promising results in treating a variety of cancers, including melanoma, lung, kidney, bladder, and head and neck cancers. It has also demonstrated efficacy in hematological malignancies. Checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines are some of the widely used immunotherapies in oncology.
Checkpoint inhibitors are drugs that block proteins that prevent immune cells from attacking cancer cells. They have shown significant efficacy in treating various malignancies, with PD-1/PD-L1 and CTLA-4 inhibitors being the most commonly used.
CAR-T therapy involves genetically modifying a patient's T cells to express receptors specific to cancer cells, enabling them to recognize and kill the target cells. This therapy has shown remarkable results in treating hematological malignancies.
Immunotherapy has transformed the landscape of cancer treatment, offering hope to patients with previously untreatable diseases. Understanding the fundamentals of immunotherapy is crucial for physicians to fully appreciate its potential and to navigate the challenges associated with its use. As research progresses, the potential for immunotherapy continues to expand, promising a brighter future for cancer patients.
1.
Combo Therapy Boosts Early CML Response but Not Long Term
2.
PNH With Extravascular Hemolysis Approves Factor D Inhibitor.
3.
In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.
4.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
5.
Classifying childhood brain cancers by immune response may improve diagnostics and treatments
1.
Precision Oncology: Integrating Genomics and Data to Shape Cancer Care’s Future
2.
Decoding Hamartomas: Understanding Their Causes and Symptoms
3.
Understanding the Silent Threat: Unveiling Prostate Cancer Symptoms
4.
Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era
5.
Breaking Barriers: Innovative Approaches in Brain Tumor Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
3.
Efficient Management of First line ALK-rearranged NSCLC
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation